Economics of Innovation
Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.
The UK Biotech Sector and Brexit: Past Performance and Future Prospects
1 April 2018
This seminar briefing examines (1) why the UK has not produced large biotech firms that develop drugs, similar to those in the United States (US), (2)…
Barriers to Uptake of Minimal Access Surgery in the United Kingdom
1 March 2018
Surgical practice has and continues to develop at a tremendous pace, reflecting the evolving technological landscape as well as the expanding skillset of the surgical workforce.…
Review of CRA’s Report “Assessing the Economic Impacts of Changing Exemption Provisions During Patent and SPC Protection in Europe”
1 January 2018
The CRA Report has an underlying assumption that the EU is as globally competitive in generics and biosimilars as it is in innovative products. There is…
Routine Funding in the UK NHS of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure
18 December 2017
This report analyses patient access in the UK to new medicines authorised via the centralised procedure between 2011 and 2016.
Public Health and Economic Implications of the United Kingdom Exiting the EU and the Single Market
12 December 2017
This report explores the consequences of the exit of the United Kingdom (UK) from the European Union (EU) on public health in the UK and in…
OHE at ISPOR’s 20th Annual European Congress: Presentations
24 November 2017
Presentations from ISPOR’s 20th Annual European Congress by staff at The Office of Health Economics are now available online
Opportunities for Utilising ‘Real World Data’ in South Korea
20 October 2017
OHE publishes a report assessing the capacity in South Korea for the collection and use of real-world data in health care.
What do Pharmaceuticals Really Cost in the Long Run?
6 October 2017
Drug prices in the US might overstate pharmaceuticals’ long-run cost up to 75%. True long-term costs then must be considered by market access and policy decisions.
OHE Lunchtime Seminar: The UK Biotech Sector and Brexit: Past Performance and Future Prospects
25 September 2017
OHE Lunchtime Seminar with Sir Geoffrey Owen and Professor Michael Hopkins. The biotech sector of the US has enjoyed a success that the UK sector has…